Canaccord Genuity Initiates Coverage On Twist Bioscience with Buy Rating, Announces Price Target of $90
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
Canaccord Genuity analyst Kyle Mikson initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Buy rating and announces Price Target of $90.
Canaccord Genuity analyst Kyle Mikson initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Buy rating and announces Price Target of $90.